SCHEDULE: FMR LLC Discloses 12.6% Stake in Beam Therapeutics
Beneficial Ownership Disclosure
FMR LLC and its affiliates, including Abigail P. Johnson, reported a 12.6% beneficial ownership stake in Beam Therapeutics Inc. as of December 31, 2025.
Summary
- FMR LLC and its affiliates, along with Abigail P. Johnson, collectively reported beneficial ownership of 12,750,369.42 shares of Beam Therapeutics Inc. common stock.
- This represents 12.6% of the total outstanding common stock of Beam Therapeutics Inc.
- FMR LLC holds sole voting power over 12,719,555.00 shares and sole dispositive power over 12,750,369.42 shares.
- Abigail P. Johnson, as a Director, Chairman, and CEO of FMR LLC, is deemed to beneficially own the same aggregate amount of shares (12,750,369.42) due to her control over FMR LLC.
- The filing is an Amendment No. 11 to a Schedule 13G, indicating previous disclosures of ownership.
- The reporting persons certified that the securities were not acquired for the purpose of changing or influencing control of Beam Therapeutics Inc.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive signal, as a large, stable institutional holding by FMR LLC suggests continued confidence in Beam Therapeutics Inc., although the filing itself does not provide operational or financial performance updates.
Positives
- A significant 12.6% stake held by a major institutional investor like FMR LLC can signal confidence in Beam Therapeutics Inc.'s long-term prospects.
- The stable institutional ownership by FMR LLC, as indicated by this being Amendment No. 11, suggests a consistent investment thesis.
Risks
- While not explicitly stated as a risk by the filing, a large institutional holding could pose a risk if the institution decides to significantly reduce its stake, potentially impacting share price.
- The filing itself does not detail specific risks related to Beam Therapeutics Inc.'s operations or financial health.
Industry Context
StockSavvy.ai notes that a significant stake by a prominent asset manager like FMR LLC in a biotechnology company such as Beam Therapeutics Inc. often indicates a belief in the company's innovative potential and long-term growth trajectory within the highly specialized and capital-intensive biotech sector. Such institutional backing can provide a degree of stability and validation for the company's strategic direction, distinguishing it from smaller, less-backed ventures.
Stakeholder Impact
- Shareholders may view the continued significant ownership by FMR LLC as a positive indicator of institutional confidence in Beam Therapeutics Inc.'s value and future prospects.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC where Power of Attorney was incorporated by reference. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC where Abigail P. Johnson's Power of Attorney was incorporated by reference. |
| 2025-12-31 | Date of event which requires filing of this statement (reporting period end). |
| 2026-02-04 | Signature date of the Schedule 13G Amendment No. 11. |
Keywords
Beam Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotechnology, Common Stock, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.